Researchers seek new ways to treat prostate cancer using relugolix in combination with radiation therapy
September 27, 2023 — The American Society for Radiation Oncology (ASTRO) announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge. The Challenge aims to identify research that addresses ways prostate cancer treatments can be improved with the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix in patients who received radiation therapy. N,O-Dimethylhydroxylamine HCl
The Challenge invited researchers to propose the study of relugolix in different scenarios: with definitive radiotherapy (concomitant/adjuvant/neoadjuvant) in patients with high/very high risk, unfavorable intermediate risk and locally advanced prostate cancer; with radiotherapy as salvage therapy following treatment with curative intent; as concomitant treatment with other oral oncolytics; for synchronous oligometastatic/metastatic and oligoprogressive disease; and beyond. Proposed studies could focus on a range of areas including clinical outcome evaluations, testosterone kinetics, patient-reported outcomes, safety/adverse events, compliance/adherence and translational research.
The Sumitomo Pharma-Pfizer Alliance will award up to a cumulative $2,500,000 in research funding, approximately $800,000 to each of the three winning proposals, over the next four to five years. The winning proposals and their principal investigators are:
Paul L. Nguyen, MD, Chair of the Challenge scientific advisory team noted, “We are thrilled to support these three outstanding submissions that will advance our understanding of how best to optimize the use of relugolix with radiation to improve outcomes for patients with prostate cancer. We are grateful that Sumitomo Pharma America, Inc. and Pfizer launched this effort with ASTRO to fund new research by radiation oncologists and our ASTRO members.”
A panel of ASTRO members with clinical, research, diversity and inclusion, and statistical expertise served on the Challenge’s scientific advisory team and judging panel to ensure that proposals were science-driven, identified the most promising research and were reviewed with an equity lens.
For more information: www.astro.org
Find more ASTR23 coverage here
October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...
October 11, 2023 — A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth ...
A University of Miami Radiation Oncology department summary noted: “In radiation oncology, the art of patient care meets ...
Tune in to ITN’s latest “One on One” video series with Michael Butkus, PhD, for insights into proton therapy ...
October 9, 2023 — SamanTree Medical, a medical technology company specializing in innovative solutions to improve cancer ...
October 9, 2023 — mTuitive, a leading provider of data enablement solutions for healthcare, announced its groundbreaking ...
October 9, 2023 — CIVCO Radiotherapy and Qfix announced the launch of a new brand, CQ Medical. This brand reflects the ...
October 6, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, and Leeds ...
October 6, 2023 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging ...
Hydroxypropyl Beta Cyclodextrin Here is a look at the most-read content during the month of September on itnonline.com: 1. PET Radiotracer Market ...